Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Dexametason mot stress och immunsystemets mekanismer bakom alkoholbegär

28 september 2026 uppdaterad av: Helen Fox, Stony Brook University

Dexametason för att inrikta sig på stress och immunsystemförändringar under tidig avhållsamhet hos individer med alkoholmissbruk (AUD)

This is a double-blind, placebo-controlled, proof of concept laboratory study to recruit N=70 (35 Males / 35 Females) non-treatment seeking, heavy drinkers with alcohol use disorder (AUD). It is hypothesized that randomization to 1.5mgs dexamethasone versus placebo will decrease alcohol craving during stress by decreasing basal cortisol, increasing anti-inflammatory cytokine levels and potentially normalizing the immune response to stress.

Studieöversikt

Status

Avslutad

Betingelser

Studietyp

Interventionell

Inskrivning (Faktisk)

27

Fas

  • Tidig fas 1

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studieorter

    • New York
      • Stony Brook, New York, Förenta staterna, 11794
        • The Health Sciences Center

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

18 år till 55 år (Vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Allt

Beskrivning

Inclusion Criteria:

  • Non-treatment seeking heavy drinking men and women with AUD
  • Age range 18-55,
  • Body Mass Index (BMI) of 18-35
  • Positive ethylglucuronide (EtG) urine toxicology screen for alcohol
  • Able to provide informed written and verbal consent
  • Able to read English and complete study evaluations
  • Good health as verified by screening examination.

Exclusion Criteria:

  • Meet criteria for Substance Use Disorder (SUD) or other psychoactive substances, excluding nicotine
  • Unable to remain abstinent for five days
  • Need for a medically assisted detoxification
  • Regular use of steroids, anticonvulsants, sedatives/hypnotics, prescription analgesics, other anti-hypertensives, anti-arrythmics, antiretroviral medications, tricyclic antidepressants, naltrexone, disulfiram, and any other psychoactive medications with the exception of stabilization on Selective Serotonin Re-uptake Inhibitors (SSRIs)
  • Psychotic or severely psychiatrically disabled
  • Significant underlying medical conditions which would be of potential harm
  • Pregnancy or breast feeding women;
  • Women using monophasic contraceptives
  • Electrocardiogram (EKG) evidence of clinically significant conduction abnormalities, (Bazlett's corrected QT (QTc) interval of >450 msec for men and QTc>470 msec for women).

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Behandling
  • Tilldelning: Randomiserad
  • Interventionsmodell: Parallellt uppdrag
  • Maskning: Dubbel

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Aktiv komparator: Guanfacine

single dose of dexamethasone (1.5mg) administered orally

1.5mg oral dexamethasone to be administered once at 11:00PM

Andra namn:
  • Decadron, Dexamethason Intensol, Dexasone, Solurex och Baycadron.
Placebo-jämförare: Placebo

single dose of placebo administered orally

oral placebo to be administered once at 11:00PM

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Alcohol craving as assessed using subjective report following stress exposure
Tidsram: Change from baseline to +5 minutes following stress exposure

The 8-item Alcohol Urges Questionnaire (AUQ) will be used to measure alcohol craving. There are 8 items, each with a Likert scale response from 1 to 7 (1: Strongly Disagree, 7: Strongly Agree). Total possible score of 56. The higher the score the higher the alcohol craving

Change from baseline to +5 minutes following stress exposure
Alcohol craving as assessed using subjective report following stress exposure
Tidsram: Change from baseline to +15 minutes following stress exposure

The 8-item Alcohol Urges Questionnaire (AUQ) will be used to measure alcohol craving. There are 8 items, each with a Likert scale response from 1 to 7 (1: Strongly Disagree, 7: Strongly Agree). Total possible score of 56. The higher the score the higher the alcohol craving

Change from baseline to +15 minutes following stress exposure
Alcohol craving as assessed using subjective report following stress exposure
Tidsram: Change from baseline to +30 minutes following stress exposure

The 8-item Alcohol Urges Questionnaire (AUQ) will be used to measure alcohol craving. There are 8 items, each with a Likert scale response from 1 to 7 (1: Strongly Disagree, 7: Strongly Agree). Total possible score of 56. The higher the score the higher the alcohol craving

Change from baseline to +30 minutes following stress exposure
Alcohol craving as assessed using subjective report following stress exposure
Tidsram: Change from baseline to +5 minutes following stress exposure

A visual analog scale will be used to measure alcohol craving. Participants will be required to rate "how much they are craving alcohol right at this moment". The scale will be anchored from 1 to 10 (1: Not at all, 10: Extremely)

Change from baseline to +5 minutes following stress exposure
Alcohol craving as assessed using subjective report following stress exposure
Tidsram: Change from baseline to +15 minutes following stress exposure

A visual analog scale will be used to measure alcohol craving. Participants will be required to rate "how much they are craving alcohol right at this moment". The scale will be anchored from 1 to 10 (1: Not at all, 10: Extremely)

Change from baseline to +15 minutes following stress exposure
Alcohol craving as assessed using subjective report following stress exposure
Tidsram: Change from baseline to +30 minutes following stress exposure

A visual analog scale will be used to measure alcohol craving. Participants will be required to rate "how much they are craving alcohol right at this moment". The scale will be anchored from 1 to 10 (1: Not at all, 10: Extremely)

Change from baseline to +30 minutes following stress exposure
Hypothalamic-Pituitary-Adrenal (HPA)-axis response to stress exposure as assessed by cortisol
Tidsram: Change from baseline to +5 minutes following stress exposure

4mls of plasma cortisol will be collected following exposure to stress

Change from baseline to +5 minutes following stress exposure
HPA axis response to stress exposure as assessed by cortisol
Tidsram: Change from baseline to +15 minutes following stress exposure

4mls of plasma cortisol will be collected following exposure to stress

Change from baseline to +15 minutes following stress exposure
HPA axis response to stress exposure as assessed by cortisol
Tidsram: Change from baseline to +30 minutes following stress exposure

4mls of plasma cortisol will be collected following exposure to stress

Change from baseline to +30 minutes following stress exposure
HPA axis response to stress exposure as assessed by Adrenocorticotropic Hormone (ACTH)
Tidsram: Change from baseline to +5 minutes following stress exposure

4mls of plasma ACTH will be collected following exposure to stress

Change from baseline to +5 minutes following stress exposure
HPA axis response to stress exposure as assessed by ACTH
Tidsram: Change from baseline to +15 minutes following stress exposure

4mls of plasma ACTH will be collected following exposure to stress

Change from baseline to +15 minutes following stress exposure
HPA axis response to stress exposure as assessed by ACTH
Tidsram: Change from baseline to +30 minutes following stress exposure

4mls of plasma ACTH will be collected following exposure to stress

Change from baseline to +30 minutes following stress exposure
Immune system response to stress exposure as assessed by peripheral cytokines
Tidsram: Change from baseline to +5 minutes following stress exposure

4mls of plasma Interleukin (IL)-10 will be collected following exposure to stress

Change from baseline to +5 minutes following stress exposure
Immune system response to stress exposure as assessed by peripheral cytokines
Tidsram: Change from baseline to +15 minutes following stress exposure

4mls of plasma IL-10 will be collected following exposure to stress

Change from baseline to +15 minutes following stress exposure
Immune system response to stress exposure as assessed by peripheral cytokines
Tidsram: Change from baseline to +30 minutes following stress exposure

4mls of plasma IL-10 will be collected following exposure to stress

Change from baseline to +30 minutes following stress exposure
Immune system response to stress exposure as assessed by peripheral cytokines
Tidsram: Change from baseline to +5 minutes following stress exposure

4mls of plasma Interleukin 1 receptor antagonist (IL1-ra) will be collected following exposure to stress

Change from baseline to +5 minutes following stress exposure
Immune system response to stress exposure as assessed by peripheral cytokines
Tidsram: Change from baseline to +15 minutes following stress exposure

4mls of plasma IL1-ra will be collected following exposure to stress

Change from baseline to +15 minutes following stress exposure
Immune system response to stress exposure as assessed by peripheral cytokines
Tidsram: Change from baseline to +30 minutes following stress exposure

4mls of plasma IL1-ra will be collected following exposure to stress

Change from baseline to +30 minutes following stress exposure
Immune system response to stress exposure as assessed by peripheral cytokines
Tidsram: Change from baseline to +5 minutes following stress exposure

4mls of plasma IL-6 will be collected following exposure to stress

Change from baseline to +5 minutes following stress exposure
Immune system response to stress exposure as assessed by peripheral cytokines
Tidsram: Change from baseline to +15 minutes following stress exposure

4mls of plasma IL-6 will be collected following exposure to stress

Change from baseline to +15 minutes following stress exposure
Immune system response to stress exposure as assessed by peripheral cytokines
Tidsram: Change from baseline to +30 minutes following stress exposure

4mls of plasma IL-6 will be collected following exposure to stress

Change from baseline to +30 minutes following stress exposure
Immune system response to stress exposure as assessed by peripheral cytokines
Tidsram: Change from baseline to +5 minutes following stress exposure

4mls of plasma Tumor Necrosis Factor alpha (TNFa) will be collected following exposure to stress

Change from baseline to +5 minutes following stress exposure
Immune system response to stress exposure as assessed by peripheral cytokines
Tidsram: Change from baseline to +15 minutes following stress exposure

4mls of plasma TNFa will be collected following exposure to stress

Change from baseline to +15 minutes following stress exposure
Immune system response to stress exposure as assessed by peripheral cytokines
Tidsram: Change from baseline to +30 minutes following stress exposure

4mls of plasma TNFa will be collected following exposure to stress

Change from baseline to +30 minutes following stress exposure
Immune system response to stress exposure as assessed by peripheral cytokines
Tidsram: Change from baseline to +5 minutes following stress exposure

4mls of plasma Tumor Necrosis Factor Receptor 1 (TNFR1) will be collected following exposure to stress

Change from baseline to +5 minutes following stress exposure
Immune system response to stress exposure as assessed by peripheral cytokines
Tidsram: Change from baseline to +15 minutes following stress exposure

4mls of plasma TNFR1 will be collected following exposure to stress

Change from baseline to +15 minutes following stress exposure
Immune system response to stress exposure as assessed by peripheral cytokines
Tidsram: Change from baseline to +30 minutes following stress exposure

4mls of plasma TNFR1 will be collected following exposure to stress

Change from baseline to +30 minutes following stress exposure

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Anxiety as assessed using subjective report following stress exposure
Tidsram: Change from baseline to +5 minutes following stress exposure

A visual analog scale will be used to measure anxiety. Participants will be required to rate "how nervous, anxious or jittery they are feeling at this moment". The scale will be anchored from 1 to 10 (1: Not at all, 10: Extremely)

Change from baseline to +5 minutes following stress exposure
Anxiety as assessed using subjective report following stress exposure
Tidsram: Change from baseline to +15 minutes following stress exposure

A visual analog scale will be used to measure anxiety. Participants will be required to rate "how nervous, anxious or jittery they are feeling at this moment". The scale will be anchored from 1 to 10 (1: Not at all, 10: Extremely)

Change from baseline to +15 minutes following stress exposure
Anxiety as assessed using subjective report following stress exposure
Tidsram: Change from baseline to +30 minutes following stress exposure

A visual analog scale will be used to measure anxiety. Participants will be required to rate "how nervous, anxious or jittery they are feeling at this moment". The scale will be anchored from 1 to 10 (1: Not at all, 10: Extremely)

Change from baseline to +30 minutes following stress exposure
Negative Mood as assessed using subjective report following stress exposure
Tidsram: Change from baseline to +5 minutes following stress exposure

The Differential Emotion Scale will be used to measure negative mood. Participants will be required to rate on a 5-point scale the extent to which an emotional word describes the way they feel at the current time. 1: not at all, 5: Extremely

Change from baseline to +5 minutes following stress exposure
Negative Mood as assessed using subjective report following stress exposure
Tidsram: Change from baseline to +15 minutes following stress exposure

The Differential Emotion Scale will be used to measure negative mood. Participants will be required to rate on a 5-point scale the extent to which an emotional word describes the way they feel at the current time. 1: not at all, 5: Extremely

Change from baseline to +15 minutes following stress exposure
Negative Mood as assessed using subjective report following stress exposure
Tidsram: Change from baseline to +30 minutes following stress exposure

The Differential Emotion Scale will be used to measure negative mood. Participants will be required to rate on a 5-point scale the extent to which an emotional word describes the way they feel at the current time. 1: not at all, 5: Extremely

Change from baseline to +30 minutes following stress exposure

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Utredare

  • Huvudutredare: Helen C Fox, PhD, Indiana University School of Medicine, Dept. of Psychiatry

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

11 mars 2022

Primärt slutförande (Faktisk)

23 juni 2024

Avslutad studie (Faktisk)

30 juni 2024

Studieregistreringsdatum

Först inskickad

22 mars 2022

Först inskickad som uppfyllde QC-kriterierna

22 mars 2022

Första postat (Faktisk)

31 mars 2022

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

2 oktober 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

28 september 2026

Senast verifierad

1 september 2026

Mer information

Termer relaterade till denna studie

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

NEJ

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Ja

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

produkt tillverkad i och exporterad från U.S.A.

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera